


**In the Specification:**

Please amend the following pages of the specification:

Page 16

--Example 3: 4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate, as follows. A solution containing 1-N-BOC-4-(3, 4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (329 mg, 0.579 mmol) and DCM (5 mL) was stirred at room temperature and TFA (5 mL) was slowly added. After 18 h, the solution was concentrated, and the residue partitioned between DCM and sat. aq.  $\text{NaHCO}_3$ . The organic layer was removed and the basic aq. layer was extracted with additional DCM (2x). The organic extracts were combined, dried, filtered, and concentrated. The residue was purified by chromatography (0-5% MeOH/DCM w/0.5% aq.  $\text{NH}_3$ ) and converted to the citrate salt to give the title compound as a white powder. MS  $m/z$  468 (M+H).—

Pages 17-18

--Example 4: 1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate, as follows. A solution containing 4-(3, 4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (103 mg, 0.22 mmol), formic acid (0.25 mL), and 37% aq. formaldehyde (2 mL) was heated at 100°C for 18h, then cooled and concentrated. The residue was partitioned between DCM and sat. aq. NaHCO<sub>3</sub> and the organic layer was removed. The basic aq. layer was extracted with additional DCM (2x), and the combined organic extracts were dried, filtered, and concentrated. The residue was purified by chromatography (Chromatotron-silica rotor) (5% MeOH/DCM w/0.5% aq. NH<sub>3</sub>) and converted to the citrate salt to give the title compound as a white powder. MS m/z 482 (M+H).--

Page 18

--Example 5: 4-(4-Chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate, as follows. In the same manner as Example 3, but using 1-N-BOC-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (350 mg,

0.655 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 434 (M+H).--

Page 19

--Example 6: 1-N-Methyl-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate, as follows. In the same manner as Example 4, but using 4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (71.5 mg, 0.165 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 448 (M+H).--

Page 20

--Example 7: 1-N-(2-Methoxyethyl)-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate, as follows. A solution containing 4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (38.5 mg, 0.089 mmol), 2-bromoethyl methyl ether (55.5 mg, 0.40 mmol), TEA (0.075 mL), and DMF (0.5 mL) was heated (microwave) at 60°C for 1.25 h, stirred at RT overnight, diluted with EtOAc, then washed successively with water (2x) and sat. aq. NaHCO<sub>3</sub>. The organic phase was dried, filtered, and concentrated. The residue was purified by chromatography (2-5% MeOH/DCM w/0.5% aq. NH<sub>3</sub>), converted to the citrate salt, and isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 492 (M+H).--

Page 20

--Example 8: 4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate, as follows. In the same manner as Example 3, but using 1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (801 mg, 1.34 mmol), TFA (25 mL), and DCM (25 mL), the citrate salt of to yield the title compound as a white, foamy solid. MS m/z 498 (M+H).--

Page 21

--Example 9: 4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate, as follows. In the same manner as Example 3, but using 1-N-BOC-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (166.8 mg, 0.294 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 466 (M+H).--

Page 22

--Example 10: 1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate, as follows. In the same manner as Example 4, but using 4-(3, 4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (69 mg, 0.148 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound as a white powder. MS m/z 480 (M+H).--

Pages 22-23

--Example 11: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt as follows. To a solution containing 3-cyano-1-naphthoic acid (0.435 g, 2.21 mmol), 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine (0.539 g, 2.43 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.676 g, 3.53 mmol) and 1-hydroxybenzotriazole (0.600 g, 4.44 mmol) in DCM (20 mL) was added TEA (0.92 mL, 6.60mmol). The solution was stirred at room temperature overnight. The mixture was partitioned between DCM and sat. NaHCO<sub>3</sub>, the organic layer was removed, and the aq. layer extracted with DCM (2x). The organic extracts were combined, dried, filtered, and concentrated. The residue was purified by chromatography (1-5% MeOH-DCM w/1% aq. NH<sub>3</sub>) to give the title compound as a white solid (0.7 g, 79% yield). MS m/z 402.50 (M+H). The citrate salt was obtained by standard procedure.--

Pages 23-24

--Example 12: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt in the same manner as Example 11, but using 3-cyano-2-methoxy-1-naphthoic acid (100 mg, 0.44 mmol), 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine (107 mg, 0.48 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (135 mg, 0.704 mmol), 1-hydroxybenzotriazole (119 mg, 0.88 mmol), DCM (5 mL), and TEA (0.184 mL, 1.32 mmol), to yield the title compound as a white solid. 74% yield, MS m/z 432.46 (M+H).--

Page 24

--Example 13: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate salt as follows. To a solution containing 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine (98 mg, 0.441 mmol) and TEA (0.13 mL, 0.933 mmol) in DCM (5 mL) was added 3-cyano-2-ethyl-1-naphthoic acid (108 mg, 0.443 mmol) in DCM (1 mL) at 0°C. The solution was stirred at 0°C for 30 min and room temperature overnight. The

mixture was partitioned between DCM and sat.  $\text{NaHCO}_3$ , the organic layer was removed, and the aq. layer extracted with DCM (2x). The organic extracts were combined, dried, filtered, and concentrated. The residue was purified by chromatography (1-5% MeOH-DCM w/1% aq.  $\text{NH}_3$ ) to give the title compound as a light yellow solid (156 mg, 82% yield). MS  $m/z$  430.51 (M+H). The citrate salt was obtained by standard procedure.--

Page 27

--Example 39: 4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate in the same manner as Example 3, but using 1-N-BOC-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine (158 mg, 0.324 mmol), to yield the title compound as a white powder. MS  $m/z$  388 (M+H).--

Pages 28-29

--Example 40: 4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl)piperidine.

The title compound of the following structure







was prepared as a citrate in the same manner as Example 3, but using 1-N-BOC-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine (1.5 g, 2.99 mmol), to yield the title compound as a white powder. MS  $m/z$  402 (M+H).--

Page 29

--Example 41: 4-(4-Fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine.

The title compound of the following structure




was prepared as a citrate in the same manner as Example 3, but using 3-cyano-2-methoxy-1-naphthoic acid instead of 3-cyano-1-naphthoic acid in 3a, to yield the title compound as a white powder. MS  $m/z$  418 (M+H).--

Pages 29-30

--Example 42: 4-(4-Fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate in the same manner as Example 3, to yield the title compound as a white powder. MS m/z 416 (M+H).--

Page 30

--Example 43: 4-(4-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate in the same manner as Example 42, but using 3-cyano-2,4-dimethoxy-1-naphthoyl chloride instead of 3-cyano-2-ethyl-1-naphthoyl chloride, to yield the title compound as a white powder. MS m/z 448 (M+H).--

Pages 30-31

--Example 44: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate in the same manner as Example 13, but using 3-cyano-2,4-dimethoxy-1-naphthoyl chloride instead of 3-cyano-2-ethyl-1-naphthoyl chloride, to yield the title compound as a white powder. MS m/z 462 (M+H).--

Page 31

--Example 45: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-fluoronaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate in the same manner as Example 11, but using 4-fluoro-1-naphthoic acid instead of 3-cyano-1-naphthoic acid, to yield the title compound as a white powder. MS m/z 395 (M+H).--

Page 32

--Example 47: 1-N-Methyl-4-(3,4-difluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate in the same manner as Example 45, but using 1-N-methyl-4-(3,4difluorophenyl)-4-(aminomethyl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine, to yield the title compound as a light yellow powder. MS m/z 480 (M+H).--

Page 32

--~~Example 46:~~ Example 48: 1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate in the same manner as Example 11, but using 1-N-ethyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine, to yield the title compound as a white powder. MS  $m/z$  416 (M+H).--

Page 33

--Example 49: 1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate in the same manner as Example 12, but using 1-N-ethyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine, to yield the title compound as a white powder. MS  $m/z$  446 (M+H).--

Page 34

--Example 51: 1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate in the same manner as Example 13, but using 1-N-ethyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine, to yield the title compound as a light yellow powder. MS  $m/z$  444 (M+H).--

Pages 34-35

--Example 52: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate in the same manner as Example 45, but using 1-N-ethyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine instead of 1-N-methyl-4-(4-fluorophenyl)-4-(aminomethyl)piperidine, to yield the title compound as a white powder. MS  $m/z$  476 (M+H).--

Page 35

--Example 53: 1-N-Ethyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-ethyl-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine (76 mg, 0.265 mmol) and 3-cyano-2-methoxy-1-naphthoyl chloride (71 mg, 0.29 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (116 mg) (63%) as a white powder. MS m/z 496 (M+H).--

Pages 36-37

--Example 54: 1-N-Ethyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-ethyl-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine (151 mg, 0.525 mmol) and 3-cyan-1-naphthoyl chloride (124 mg, 0.577 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound ~~115 mg~~ (115 mg) (76%) as a white powder. MS m/z 466 (M+H).--

Page 37

--Example 55: 1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 11, but using 1-N-methyl-4-aminomethyl-4-(3,4-dichlorophenyl)piperidine (237 mg, 0.867 mmol) and 3-cyano-1-naphthoic acid (168 mg, 0.852 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (306 mg) (57%) as a white powder. MS m/z 452 (M+H).--

Page 37

--Example 56: 1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



was prepared as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(3-fluorophenyl) piperidine (172 mg, 0.775 mmol) and 3-cyano-1-naphthoic acid




chloride (164.5 mg, 0.763 mmol), the title compound (139 mg) (45%) was obtained as a white powder. MS m/z 402 (M+H).--

Page 38

--Example 57: 1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(3-fluorophenyl)piperidine (166.2 mg, 0.748 mmol) and 3-cyano-2-methoxy-1-naphthoyl chloride (178.8 mg, 0.728 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (325 mg) (72%) as a white powder. MSm/z 432 (M+H).--

Pages 38-39

--Example 58: 1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(3-fluorophenyl)piperidine (151.9 mg, 0.683 mmol) and 3-cyano-2-ethyl-1-naphthoyl chloride (163.2 mg, 0.67 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (272 mg) (65%) as a white powder. MS m/z 430 (M+H).--

Page 39

--Example 59: 1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(3-fluorophenyl)piperidine (154.8 mg, 0.696 mmol) and 3-cyano-2,4-dimethoxy-1-naphthoyl chloride (187.3 mg, 0.679 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (247 mg) (55%) as a white powder. MS m/z 462 (M+H).--

Page 39

--Example 60: 1-N-Methyl-4-phenyl-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure





was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-phenylpiperidine (159 mg, 0.776 mmol) and 3-cyano-1-naphthoyl chloride (164.5 mg, 0.763 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (278 mg) (65%) as a white powder. MS m/z 384 (M+H).--

Page 40

--Example 61: 1-N-Methyl-4-phenyl-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-phenylpiperidine (151 mg, 0.738 mmol) and 3-cyano-2-methoxy-1-naphthoyl chloride (175 mg, 0.713 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (381 mg) (90%) as a white powder. MS m/z 414 (M+H).--

Pages 40-41

--Example 62: 1-N-Methyl-4-phenyl-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-phenylpiperidine (140.4 mg, 0.687 mmol) and 3-cyano-2-ethyl-1-naphthoyl chloride (163.2 mg, 0.67 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (257 mg) (64%) as a white powder. MS m/z 412 (M+H).--

Page 41

--Example 63: 1-N-Methyl-4-phenyl-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-phenylpiperidine (147.5 mg, 0.722 mmol) and 3-cyano-2,4-dimethoxy-1-naphthoyl chloride (187.3 mg, 0.679 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (171 mg) (39%) as a white powder. MS m/z 444 (M+H).--

Pages 41-42

--Example 65: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-methoxy-4-methylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(4-fluorophenyl)piperidine (107.5 mg, 0.484 mmol) and 3-methoxy-4-methyl-1-naphthoyl chloride (108.5 mg, 0.462mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (217 mg) (78%) as a white powder. MS m/z 421 (M+H).--

Page 42

--Example 66: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-chloro-3-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(4-fluorophenyl)piperidine (107 mg, 0.48 mmol) and 4-chloro-3-

methoxy-1-naphthoyl chloride (115.5 mg, 0.453 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (187 mg) (67%) as a white powder. MS m/z 441 (M+H).--

Pages 42-43

--Example 67: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-4-methylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure




was prepared as a citrate salt, as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(4-fluorophenyl)piperidine (122 mg, 0.549 mmol) and 3-cyano-4-methyl-1-naphthoyl chloride (110.9 mg, 0.483 mmol), the citrate salt was isolated by filtration from Et<sub>2</sub>O to give the title compound (224 mg) (76%) as a white powder. MS m/z 416 (M+H).--

Page 43

--Example 69: 1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-bromonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine.

The title compound of the following structure



was prepared as follows. In the same manner as Example 13, but using 1-N-methyl-4-aminomethyl-4-(4-fluorophenyl)piperidine (174.6 mg, 0.785 mmol) and 4-bromo-1-naphthoyl chloride (177 mg, 0.656 mmol), the title compound (214 mg) (71%) was obtained as a white powder. MS  $m/z$  455 (M+H).--